Search research articles
Contact Us
Filters
Showing results (51-60 of 71) with videos related to
Page
of 8
Sort By:
Carcinogenesis
|
June 1, 1987
Failure of the tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA) to inhibit cell-cell coupling in newborn mouse epidermal cells and Chinese hamster V79 cells under non-standard culture conditions
D R Miller, L Istone, W Burkart, et al.
Paraplegia
|
November 1, 1993
Effects of induced hypothermia on somatosensory evoked potentials in patients with chronic spinal cord injury
K C Hayes, J T Hsieh, P J Potter, et al.
Journal of Neurotrauma
|
August 1, 1994
4-Aminopyridine-sensitive neurologic deficits in patients with spinal cord injury
K C Hayes, P J Potter, D L Wolfe, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
April 19, 2007
Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study
A D Goodman, J A Cohen, A Cross, et al.
Restorative Neurology and Neuroscience
|
May 10, 2011
Effects of applied electric fields on clinical cases of complete paraplegia in dogs
R B Borgens, J P Toombs, A R Blight, et al.
Spinal Cord
|
June 15, 2006
Phase 2 trial of sustained-release fampridine in chronic spinal cord injury
D D Cardenas, J Ditunno, V Graziani, et al.
Journal of Clinical Pharmacology
|
May 2, 2003
Pharmacokinetics of an immediate-release oral formulation of Fampridine (4-aminopyridine) in normal subjects and patients with spinal cord injury
K C Hayes, M A Katz, J G Devane, et al.
Paraplegia
|
April 1, 1993
Preclinical trial of 4-aminopyridine in patients with chronic spinal cord injury
K C Hayes, A R Blight, P J Potter, et al.
Neurology
|
August 2, 2008
Dose comparison trial of sustained-release fampridine in multiple sclerosis
A D Goodman, T R Brown, J A Cohen, et al.
Spinal Cord
|
November 13, 2013
Two phase 3, multicenter, randomized, placebo-controlled clinical trials of fampridine-SR for treatment of spasticity in chronic spinal cord injury
D D Cardenas, J F Ditunno, V Graziani, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 71) with videos related to
Sort By:
Page
of 8
Carcinogenesis
|
June 1, 1987
Failure of the tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA) to inhibit cell-cell coupling in newborn mouse epidermal cells and Chinese hamster V79 cells under non-standard culture conditions
D R Miller, L Istone, W Burkart, et al.
Paraplegia
|
November 1, 1993
Effects of induced hypothermia on somatosensory evoked potentials in patients with chronic spinal cord injury
K C Hayes, J T Hsieh, P J Potter, et al.
Journal of Neurotrauma
|
August 1, 1994
4-Aminopyridine-sensitive neurologic deficits in patients with spinal cord injury
K C Hayes, P J Potter, D L Wolfe, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
April 19, 2007
Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study
A D Goodman, J A Cohen, A Cross, et al.
Restorative Neurology and Neuroscience
|
May 10, 2011
Effects of applied electric fields on clinical cases of complete paraplegia in dogs
R B Borgens, J P Toombs, A R Blight, et al.
Spinal Cord
|
June 15, 2006
Phase 2 trial of sustained-release fampridine in chronic spinal cord injury
D D Cardenas, J Ditunno, V Graziani, et al.
Journal of Clinical Pharmacology
|
May 2, 2003
Pharmacokinetics of an immediate-release oral formulation of Fampridine (4-aminopyridine) in normal subjects and patients with spinal cord injury
K C Hayes, M A Katz, J G Devane, et al.
Paraplegia
|
April 1, 1993
Preclinical trial of 4-aminopyridine in patients with chronic spinal cord injury
K C Hayes, A R Blight, P J Potter, et al.
Neurology
|
August 2, 2008
Dose comparison trial of sustained-release fampridine in multiple sclerosis
A D Goodman, T R Brown, J A Cohen, et al.
Spinal Cord
|
November 13, 2013
Two phase 3, multicenter, randomized, placebo-controlled clinical trials of fampridine-SR for treatment of spasticity in chronic spinal cord injury
D D Cardenas, J F Ditunno, V Graziani, et al.
Page
of 8